» Articles » PMID: 38383522

Converging and Evolving Immuno-genomic Routes Toward Immune Escape in Breast Cancer

Abstract

The interactions between tumor and immune cells along the course of breast cancer progression remain largely unknown. Here, we extensively characterize multiple sequential and parallel multiregion tumor and blood specimens of an index patient and a cohort of metastatic triple-negative breast cancers. We demonstrate that a continuous increase in tumor genomic heterogeneity and distinct molecular clocks correlated with resistance to treatment, eventually allowing tumors to escape from immune control. TCR repertoire loses diversity over time, leading to convergent evolution as breast cancer progresses. Although mixed populations of effector memory and cytotoxic single T cells coexist in the peripheral blood, defects in the antigen presentation machinery coupled with subdued T cell recruitment into metastases are observed, indicating a potent immune avoidance microenvironment not compatible with an effective antitumor response in lethal metastatic disease. Our results demonstrate that the immune responses against cancer are not static, but rather follow dynamic processes that match cancer genomic progression, illustrating the complex nature of tumor and immune cell interactions.

Citing Articles

CD4FOXP3Exon2 regulatory T cell frequency predicts breast cancer prognosis and survival.

Fusco C, Di Rella F, Liotti A, Colamatteo A, Ferrara A, Gigantino V Sci Adv. 2025; 11(3):eadr7934.

PMID: 39813341 PMC: 11734725. DOI: 10.1126/sciadv.adr7934.


Single-cell and spatial omics unravel the spatiotemporal biology of tumour border invasion and haematogenous metastasis.

Cheng X, Cao Y, Liu X, Li Y, Li Q, Gao D Clin Transl Med. 2024; 14(10):e70036.

PMID: 39350478 PMC: 11442492. DOI: 10.1002/ctm2.70036.


Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation.

Zhang Y, Yeganeh P, Zhang H, Wang S, Li Z, Gu B Nat Immunol. 2024; 25(10):1858-1870.

PMID: 39169233 DOI: 10.1038/s41590-024-01932-8.


Discovery of oxazine-linked pyrimidine as an inhibitor of breast cancer growth and metastasis by abrogating NF-κB activation.

Yuan J, Narasimhachar B, Ravish A, Yang L, Zhang H, Wang Q Front Oncol. 2024; 14:1390992.

PMID: 39135991 PMC: 11317417. DOI: 10.3389/fonc.2024.1390992.

References
1.
Rempala G, Seweryn M . Methods for diversity and overlap analysis in T-cell receptor populations. J Math Biol. 2012; 67(6-7):1339-68. PMC: 3543521. DOI: 10.1007/s00285-012-0589-7. View

2.
Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

3.
Shugay M, Bagaev D, Turchaninova M, Bolotin D, Britanova O, Putintseva E . VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires. PLoS Comput Biol. 2015; 11(11):e1004503. PMC: 4659587. DOI: 10.1371/journal.pcbi.1004503. View

4.
Narang P, Chen M, Sharma A, Anderson K, Wilson M . The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer. 2019; 19(1):200. PMC: 6399957. DOI: 10.1186/s12885-019-5402-1. View

5.
McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S . Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351(6280):1463-9. PMC: 4984254. DOI: 10.1126/science.aaf1490. View